Cholangiocarcinoma  ||| S:0 E:19 ||| NNP
Heterogeneity  ||| S:19 E:33 ||| NNP
Revealed  ||| S:33 E:42 ||| NNP
by  ||| S:42 E:45 ||| IN
Multigene  ||| S:45 E:55 ||| NNP
Mutational  ||| S:55 E:66 ||| NNP
Profiling ||| S:66 E:75 ||| NNP
:  ||| S:75 E:77 ||| :
Clinical  ||| S:77 E:86 ||| NNP
and  ||| S:86 E:90 ||| CC
Prognostic  ||| S:90 E:101 ||| NNP
Relevance  ||| S:101 E:111 ||| NNP
in  ||| S:111 E:114 ||| IN
Surgically  ||| S:114 E:125 ||| NNP
Resected  ||| S:125 E:134 ||| NNP
Patients  ||| S:134 E:143 ||| NNPS
Cholangiocarcinoma  ||| S:143 E:162 ||| NNP
can  ||| S:162 E:166 ||| MD
be  ||| S:166 E:169 ||| VB
classified  ||| S:169 E:180 ||| VBN
in  ||| S:180 E:183 ||| IN
intrahepatic  ||| S:183 E:196 ||| JJ
cholangiocarcinoma  ||| S:196 E:215 ||| NNS
( ||| S:215 E:216 ||| -LRB-
ICC ||| S:216 E:219 ||| NNP
)  ||| S:219 E:221 ||| -RRB-
and  ||| S:221 E:225 ||| CC
perihilar  ||| S:225 E:235 ||| JJ
cholangiocarcinoma  ||| S:235 E:254 ||| NNS
( ||| S:254 E:255 ||| -LRB-
PCC ||| S:255 E:258 ||| NNP
) ||| S:258 E:259 ||| -RRB-
.  ||| S:259 E:261 ||| .
Moreover ||| S:261 E:269 ||| RB
,  ||| S:269 E:271 ||| ,
PCC  ||| S:271 E:275 ||| NNP
includes  ||| S:275 E:284 ||| VBZ
two  ||| S:284 E:288 ||| CD
different  ||| S:288 E:298 ||| JJ
forms ||| S:298 E:303 ||| NNS
:  ||| S:303 E:305 ||| :
extrahepatic  ||| S:305 E:318 ||| CD
( ||| S:318 E:319 ||| -LRB-
EH ||| S:319 E:321 ||| NNP
)  ||| S:321 E:323 ||| -RRB-
PCC ||| S:323 E:326 ||| NNP
,  ||| S:326 E:328 ||| ,
which  ||| S:328 E:334 ||| WDT
arises  ||| S:334 E:341 ||| VBZ
from  ||| S:341 E:346 ||| IN
the  ||| S:346 E:350 ||| DT
perihilar  ||| S:350 E:360 ||| JJ
EH  ||| S:360 E:363 ||| NNP
large  ||| S:363 E:369 ||| JJ
ducts ||| S:369 E:374 ||| NNS
,  ||| S:374 E:376 ||| ,
and  ||| S:376 E:380 ||| CC
intrahepatic  ||| S:380 E:393 ||| NNS
( ||| S:393 E:394 ||| -LRB-
IH ||| S:394 E:396 ||| NNP
)  ||| S:396 E:398 ||| -RRB-
PCC ||| S:398 E:401 ||| NNP
,  ||| S:401 E:403 ||| ,
in  ||| S:403 E:406 ||| IN
which  ||| S:406 E:412 ||| WDT
a  ||| S:412 E:414 ||| DT
significant  ||| S:414 E:426 ||| JJ
liver  ||| S:426 E:432 ||| NN
mass  ||| S:432 E:437 ||| NN
invades  ||| S:437 E:445 ||| VBZ
the  ||| S:445 E:449 ||| DT
perihilar  ||| S:449 E:459 ||| JJ
bile  ||| S:459 E:464 ||| JJ
ducts ||| S:464 E:469 ||| NNS
.  ||| S:469 E:471 ||| .
In  ||| S:471 E:474 ||| IN
this  ||| S:474 E:479 ||| DT
study ||| S:479 E:484 ||| NN
,  ||| S:484 E:486 ||| ,
we  ||| S:486 E:489 ||| PRP
investigated  ||| S:489 E:502 ||| VBD
the  ||| S:502 E:506 ||| DT
molecular  ||| S:506 E:516 ||| JJ
profile  ||| S:516 E:524 ||| NN
and  ||| S:524 E:528 ||| CC
molecular  ||| S:528 E:538 ||| JJ
prognostic  ||| S:538 E:549 ||| JJ
factors  ||| S:549 E:557 ||| NNS
in  ||| S:557 E:560 ||| IN
EH-PCC ||| S:560 E:566 ||| NNP
,  ||| S:566 E:568 ||| ,
IH-PCC ||| S:568 E:574 ||| NNP
,  ||| S:574 E:576 ||| ,
and  ||| S:576 E:580 ||| CC
ICC  ||| S:580 E:584 ||| NNP
submitted  ||| S:584 E:594 ||| VBD
to  ||| S:594 E:597 ||| TO
curative  ||| S:597 E:606 ||| VB
surgery ||| S:606 E:613 ||| NN
.  ||| S:613 E:615 ||| .
Ninety-one  ||| S:615 E:626 ||| JJ
patients  ||| S:626 E:635 ||| NNS
with  ||| S:635 E:640 ||| IN
cholangiocarcinoma  ||| S:640 E:659 ||| NNS
( ||| S:659 E:660 ||| -LRB-
38  ||| S:660 E:663 ||| CD
EH-PCC ||| S:663 E:669 ||| NN
,  ||| S:669 E:671 ||| ,
18  ||| S:671 E:674 ||| CD
IH-PCC ||| S:674 E:680 ||| NN
,  ||| S:680 E:682 ||| ,
and  ||| S:682 E:686 ||| CC
35  ||| S:686 E:689 ||| CD
ICC ||| S:689 E:692 ||| NNP
) ||| S:692 E:693 ||| -RRB-
,  ||| S:693 E:695 ||| ,
who  ||| S:695 E:699 ||| WP
underwent  ||| S:699 E:709 ||| VBD
curative  ||| S:709 E:718 ||| JJ
surgery  ||| S:718 E:726 ||| NN
in  ||| S:726 E:729 ||| IN
a  ||| S:729 E:731 ||| DT
single  ||| S:731 E:738 ||| JJ
tertiary  ||| S:738 E:747 ||| JJ
hepatobiliary  ||| S:747 E:761 ||| JJ
surgery  ||| S:761 E:769 ||| NN
referral  ||| S:769 E:778 ||| NN
center  ||| S:778 E:785 ||| NN
were  ||| S:785 E:790 ||| VBD
assessed  ||| S:790 E:799 ||| VBN
for  ||| S:799 E:803 ||| IN
mutational  ||| S:803 E:814 ||| JJ
status  ||| S:814 E:821 ||| NN
in  ||| S:821 E:824 ||| IN
56  ||| S:824 E:827 ||| CD
cancer-related  ||| S:827 E:842 ||| JJ
genes ||| S:842 E:847 ||| NNS
.  ||| S:847 E:849 ||| .
The  ||| S:849 E:853 ||| DT
most  ||| S:853 E:858 ||| RBS
frequently  ||| S:858 E:869 ||| RB
mutated  ||| S:869 E:877 ||| JJ
genes  ||| S:877 E:883 ||| NNS
in  ||| S:883 E:886 ||| IN
EH-PCC  ||| S:886 E:893 ||| NNP
were  ||| S:893 E:898 ||| VBD
KRAS  ||| S:898 E:903 ||| NNP
( ||| S:903 E:904 ||| -LRB-
47.4  ||| S:904 E:909 ||| NNP
% ||| S:909 E:910 ||| NN
) ||| S:910 E:911 ||| -RRB-
,  ||| S:911 E:913 ||| ,
TP53  ||| S:913 E:918 ||| NNP
( ||| S:918 E:919 ||| -LRB-
23.7  ||| S:919 E:924 ||| NNP
% ||| S:924 E:925 ||| NN
)  ||| S:925 E:927 ||| -RRB-
and  ||| S:927 E:931 ||| CC
ARID1A  ||| S:931 E:938 ||| NNP
( ||| S:938 E:939 ||| -LRB-
15.8  ||| S:939 E:944 ||| NNP
% ||| S:944 E:945 ||| NN
) ||| S:945 E:946 ||| -RRB-
;  ||| S:946 E:948 ||| :
in  ||| S:948 E:951 ||| IN
IH-PCC  ||| S:951 E:958 ||| NNP
were  ||| S:958 E:963 ||| VBD
KRAS  ||| S:963 E:968 ||| NNP
( ||| S:968 E:969 ||| -LRB-
22.2  ||| S:969 E:974 ||| NNP
% ||| S:974 E:975 ||| NN
) ||| S:975 E:976 ||| -RRB-
,  ||| S:976 E:978 ||| ,
PBRM1  ||| S:978 E:984 ||| NNP
( ||| S:984 E:985 ||| -LRB-
16.7  ||| S:985 E:990 ||| NNP
% ||| S:990 E:991 ||| NN
) ||| S:991 E:992 ||| -RRB-
,  ||| S:992 E:994 ||| ,
and  ||| S:994 E:998 ||| CC
PIK3CA  ||| S:998 E:1005 ||| NNP
( ||| S:1005 E:1006 ||| -LRB-
16.7  ||| S:1006 E:1011 ||| NNP
% ||| S:1011 E:1012 ||| NN
) ||| S:1012 E:1013 ||| -RRB-
;  ||| S:1013 E:1015 ||| :
and  ||| S:1015 E:1019 ||| CC
in  ||| S:1019 E:1022 ||| IN
ICC  ||| S:1022 E:1026 ||| NNP
were  ||| S:1026 E:1031 ||| VBD
IDH1  ||| S:1031 E:1036 ||| CD
( ||| S:1036 E:1037 ||| -LRB-
17.1  ||| S:1037 E:1042 ||| NNP
% ||| S:1042 E:1043 ||| NN
) ||| S:1043 E:1044 ||| -RRB-
,  ||| S:1044 E:1046 ||| ,
NRAS  ||| S:1046 E:1051 ||| NNP
( ||| S:1051 E:1052 ||| -LRB-
17.1  ||| S:1052 E:1057 ||| NNP
% ||| S:1057 E:1058 ||| NN
) ||| S:1058 E:1059 ||| -RRB-
,  ||| S:1059 E:1061 ||| ,
and  ||| S:1061 E:1065 ||| CC
BAP1  ||| S:1065 E:1070 ||| NNP
( ||| S:1070 E:1071 ||| -LRB-
14.3  ||| S:1071 E:1076 ||| NNP
% ||| S:1076 E:1077 ||| NN
) ||| S:1077 E:1078 ||| -RRB-
.  ||| S:1078 E:1080 ||| .
The  ||| S:1080 E:1084 ||| DT
presence  ||| S:1084 E:1093 ||| NN
of  ||| S:1093 E:1096 ||| IN
mutations  ||| S:1096 E:1106 ||| NNS
in  ||| S:1106 E:1109 ||| IN
ALK ||| S:1109 E:1112 ||| NNP
,  ||| S:1112 E:1114 ||| ,
IDH1 ||| S:1114 E:1118 ||| NNP
,  ||| S:1118 E:1120 ||| ,
and  ||| S:1120 E:1124 ||| CC
TP53  ||| S:1124 E:1129 ||| CD
genes  ||| S:1129 E:1135 ||| NNS
was  ||| S:1135 E:1139 ||| VBD
significantly  ||| S:1139 E:1153 ||| RB
associated  ||| S:1153 E:1164 ||| VBN
with  ||| S:1164 E:1169 ||| IN
poor  ||| S:1169 E:1174 ||| JJ
prognosis  ||| S:1174 E:1184 ||| NN
in  ||| S:1184 E:1187 ||| IN
patients  ||| S:1187 E:1196 ||| NNS
with  ||| S:1196 E:1201 ||| IN
EH-PCC  ||| S:1201 E:1208 ||| NNP
( ||| S:1208 E:1209 ||| -LRB-
p   ||| S:1209 E:1211 ||| NNP
< ||| S:1211 E:1212 ||| SYM
 0.001 ||| S:1212 E:1218 ||| NNP
,  ||| S:1218 E:1220 ||| ,
p = 0.043 ||| S:1220 E:1229 ||| NNP
,  ||| S:1229 E:1231 ||| ,
and  ||| S:1231 E:1235 ||| CC
p = 0.019 ||| S:1235 E:1244 ||| NNP
,  ||| S:1244 E:1246 ||| ,
respectively ||| S:1246 E:1258 ||| RB
) ||| S:1258 E:1259 ||| -RRB-
.  ||| S:1259 E:1261 ||| .
Mutation  ||| S:1261 E:1270 ||| NN
of  ||| S:1270 E:1273 ||| IN
the  ||| S:1273 E:1277 ||| DT
TP53  ||| S:1277 E:1282 ||| JJ
gene  ||| S:1282 E:1287 ||| NN
was  ||| S:1287 E:1291 ||| VBD
significantly  ||| S:1291 E:1305 ||| RB
associated  ||| S:1305 E:1316 ||| VBN
with  ||| S:1316 E:1321 ||| IN
poor  ||| S:1321 E:1326 ||| JJ
prognosis  ||| S:1326 E:1336 ||| NN
in  ||| S:1336 E:1339 ||| IN
patients  ||| S:1339 E:1348 ||| NNS
with  ||| S:1348 E:1353 ||| IN
IH-PCC  ||| S:1353 E:1360 ||| NNP
( ||| S:1360 E:1361 ||| -LRB-
p = 0.049 ||| S:1361 E:1370 ||| NNP
) ||| S:1370 E:1371 ||| -RRB-
.  ||| S:1371 E:1373 ||| .
The  ||| S:1373 E:1377 ||| DT
presence  ||| S:1377 E:1386 ||| NN
of  ||| S:1386 E:1389 ||| IN
mutations  ||| S:1389 E:1399 ||| NNS
in  ||| S:1399 E:1402 ||| IN
ARID1A ||| S:1402 E:1408 ||| NNP
,  ||| S:1408 E:1410 ||| ,
PIK3C2G ||| S:1410 E:1417 ||| NNP
,  ||| S:1417 E:1419 ||| ,
STK11 ||| S:1419 E:1424 ||| NNP
,  ||| S:1424 E:1426 ||| ,
TGFBR2 ||| S:1426 E:1432 ||| NNP
,  ||| S:1432 E:1434 ||| ,
and  ||| S:1434 E:1438 ||| CC
TP53  ||| S:1438 E:1443 ||| CD
genes  ||| S:1443 E:1449 ||| NNS
was  ||| S:1449 E:1453 ||| VBD
significantly  ||| S:1453 E:1467 ||| RB
associated  ||| S:1467 E:1478 ||| VBN
with  ||| S:1478 E:1483 ||| IN
poor  ||| S:1483 E:1488 ||| JJ
prognosis  ||| S:1488 E:1498 ||| NN
in  ||| S:1498 E:1501 ||| IN
patients  ||| S:1501 E:1510 ||| NNS
with  ||| S:1510 E:1515 ||| IN
ICC  ||| S:1515 E:1519 ||| NNP
( ||| S:1519 E:1520 ||| -LRB-
p = 0.012 ||| S:1520 E:1529 ||| NNP
,  ||| S:1529 E:1531 ||| ,
p = 0.030 ||| S:1531 E:1540 ||| NNP
,  ||| S:1540 E:1542 ||| ,
p = 0.030 ||| S:1542 E:1551 ||| NNP
,  ||| S:1551 E:1553 ||| ,
p = 0.011 ||| S:1553 E:1562 ||| NNP
,  ||| S:1562 E:1564 ||| ,
and  ||| S:1564 E:1568 ||| CC
p = 0.011 ||| S:1568 E:1577 ||| NNP
,  ||| S:1577 E:1579 ||| ,
respectively ||| S:1579 E:1591 ||| RB
) ||| S:1591 E:1592 ||| -RRB-
.  ||| S:1592 E:1594 ||| .
Mutational  ||| S:1594 E:1605 ||| JJ
gene  ||| S:1605 E:1610 ||| NN
profiling  ||| S:1610 E:1620 ||| VBZ
identified  ||| S:1620 E:1631 ||| VBN
different  ||| S:1631 E:1641 ||| JJ
gene  ||| S:1641 E:1646 ||| NN
mutations  ||| S:1646 E:1656 ||| NNS
in  ||| S:1656 E:1659 ||| IN
EH-PCC ||| S:1659 E:1665 ||| NNP
,  ||| S:1665 E:1667 ||| ,
IH-PCC ||| S:1667 E:1673 ||| NNP
,  ||| S:1673 E:1675 ||| ,
and  ||| S:1675 E:1679 ||| CC
ICC ||| S:1679 E:1682 ||| NNP
.  ||| S:1682 E:1684 ||| .
Moreover ||| S:1684 E:1692 ||| RB
,  ||| S:1692 E:1694 ||| ,
our  ||| S:1694 E:1698 ||| PRP$
study  ||| S:1698 E:1704 ||| NN
reported  ||| S:1704 E:1713 ||| VBD
specific  ||| S:1713 E:1722 ||| JJ
prognostic  ||| S:1722 E:1733 ||| JJ
genes  ||| S:1733 E:1739 ||| NNS
that  ||| S:1739 E:1744 ||| WDT
can  ||| S:1744 E:1748 ||| MD
identify  ||| S:1748 E:1757 ||| VB
patients  ||| S:1757 E:1766 ||| NNS
with  ||| S:1766 E:1771 ||| IN
poor  ||| S:1771 E:1776 ||| JJ
prognosis  ||| S:1776 E:1786 ||| NN
after  ||| S:1786 E:1792 ||| IN
curative  ||| S:1792 E:1801 ||| JJ
surgery  ||| S:1801 E:1809 ||| NN
who  ||| S:1809 E:1813 ||| WP
may  ||| S:1813 E:1817 ||| MD
benefit  ||| S:1817 E:1825 ||| VB
from  ||| S:1825 E:1830 ||| IN
traditional  ||| S:1830 E:1842 ||| JJ
or  ||| S:1842 E:1845 ||| CC
target  ||| S:1845 E:1852 ||| NN
adjuvant  ||| S:1852 E:1861 ||| NN
treatments ||| S:1861 E:1871 ||| NNS
.  ||| S:1871 E:1873 ||| .
